BACKGROUND: Mild cognitive impairment (MCI) is associated with an increased dementia risk. This study reports incidence of MCI subtypes, rates of progression to dementia, and stability of MCI classification. METHODS: We examined 873 community-dwelling adults aged 70 to 90 years over 2 years as part of an ongoing population-based longitudinal study, the Sydney Memory and Ageing Study. Neuropsychological testing assessed five cognitive domains, and a diagnosis of no cognitive impairment, MCI, or dementia (follow-up only) was made according to published criteria. RESULTS: The incidence of MCI was 104.6 (95% confidence interval: 81.6-127.7) per 1000 person-years, with higher incidence in men (men, 156.8; women, 70.3). Incidence rates for single-domain amnestic, multiple-domain amnestic, single-domain nonamnestic, and multiple-domain nonamnestic MCI were 47.7, 7.9, 45.0, and 3.9 per 1000 person-years, respectively. The 2-year rate of progression from MCI at baseline to dementia was 4.8%, being highest for multidomain amnestic MCI (9.1%). Of those with MCI at baseline, 28.2% reverted to no cognitive impairment at follow-up. Sensitivity analyses by redefining criteria for cognitive impairment did not affect stability of diagnosis, although changing the threshold of domain impairment reduced baseline MCI prevalence from 36.7% to 5.7% and incidence to 23.5, and increased 2-year progression rate from MCI to dementia to 14.3%. CONCLUSIONS: Incidence rates for MCI are higher than previously reported, particularly in men and for single-domain MCI; rates for amnestic and nonamnestic MCI were comparable. Multidomain amnestic MCI was the most likely subtype to progress to dementia, but overall, the diagnosis of MCI, particularly single-domain MCI, shows considerable instability.
BACKGROUND: Mild cognitive impairment (MCI) is associated with an increased dementia risk. This study reports incidence of MCI subtypes, rates of progression to dementia, and stability of MCI classification. METHODS: We examined 873 community-dwelling adults aged 70 to 90 years over 2 years as part of an ongoing population-based longitudinal study, the Sydney Memory and Ageing Study. Neuropsychological testing assessed five cognitive domains, and a diagnosis of no cognitive impairment, MCI, or dementia (follow-up only) was made according to published criteria. RESULTS: The incidence of MCI was 104.6 (95% confidence interval: 81.6-127.7) per 1000 person-years, with higher incidence in men (men, 156.8; women, 70.3). Incidence rates for single-domain amnestic, multiple-domain amnestic, single-domain nonamnestic, and multiple-domain nonamnestic MCI were 47.7, 7.9, 45.0, and 3.9 per 1000 person-years, respectively. The 2-year rate of progression from MCI at baseline to dementia was 4.8%, being highest for multidomain amnestic MCI (9.1%). Of those with MCI at baseline, 28.2% reverted to no cognitive impairment at follow-up. Sensitivity analyses by redefining criteria for cognitive impairment did not affect stability of diagnosis, although changing the threshold of domain impairment reduced baseline MCI prevalence from 36.7% to 5.7% and incidence to 23.5, and increased 2-year progression rate from MCI to dementia to 14.3%. CONCLUSIONS: Incidence rates for MCI are higher than previously reported, particularly in men and for single-domain MCI; rates for amnestic and nonamnestic MCI were comparable. Multidomain amnestic MCI was the most likely subtype to progress to dementia, but overall, the diagnosis of MCI, particularly single-domain MCI, shows considerable instability.
Authors: Jeannie-Marie S Leoutsakos; Alexandra L Bartlett; Sarah N Forrester; Constantine G Lyketsos Journal: Alzheimers Dement Date: 2013-08-15 Impact factor: 21.566
Authors: Deborah E Barnes; Irena S Cenzer; Kristine Yaffe; Christine S Ritchie; Sei J Lee Journal: Alzheimers Dement Date: 2014-02-01 Impact factor: 21.566
Authors: Erin E Sundermann; Anat Biegon; Leah H Rubin; Richard B Lipton; Wenzhu Mowrey; Susan Landau; Pauline M Maki Journal: Neurology Date: 2016-03-16 Impact factor: 9.910
Authors: Erin E Sundermann; Pauline Maki; Anat Biegon; Richard B Lipton; Michelle M Mielke; Mary Machulda; Mark W Bondi Journal: Neurology Date: 2019-10-09 Impact factor: 9.910
Authors: Elena Portacolone; Julene K Johnson; Kenneth E Covinsky; Jodi Halpern; Robert L Rubinstein Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: M E López; P Cuesta; P Garcés; P N Castellanos; S Aurtenetxe; R Bajo; A Marcos; M L Delgado; P Montejo; J L López-Pantoja; F Maestú; A Fernandez Journal: Age (Dordr) Date: 2014-02-16
Authors: Erin E Sundermann; Pauline M Maki; Leah H Rubin; Richard B Lipton; Susan Landau; Anat Biegon Journal: Neurology Date: 2016-10-05 Impact factor: 9.910
Authors: Perminder S Sachdev; Darren M Lipnicki; John Crawford; Simone Reppermund; Nicole A Kochan; Julian N Trollor; Wei Wen; Brian Draper; Melissa J Slavin; Kristan Kang; Ora Lux; Karen A Mather; Henry Brodaty Journal: PLoS One Date: 2013-03-27 Impact factor: 3.240
Authors: Michelle K Lupton; Lachlan Strike; Narelle K Hansell; Wei Wen; Karen A Mather; Nicola J Armstrong; Anbupalam Thalamuthu; Katie L McMahon; Greig I de Zubicaray; Amelia A Assareh; Andrew Simmons; Petroula Proitsi; John F Powell; Grant W Montgomery; Derrek P Hibar; Eric Westman; Magda Tsolaki; Iwona Kloszewska; Hilkka Soininen; Patrizia Mecocci; Bruno Velas; Simon Lovestone; Henry Brodaty; David Ames; Julian N Trollor; Nicholas G Martin; Paul M Thompson; Perminder S Sachdev; Margaret J Wright Journal: Neurobiol Aging Date: 2016-01-11 Impact factor: 4.673